AKRO

Akero Therapeutics

This company develops metabolic disease treatments for patients with metabolic dysfunction-associated steatohepatitis and other liver conditions.

Inventiva

This biopharmaceutical company develops oral small molecule therapies for patients with metabolic dysfunction-associated steatohepatitis and other fibrotic or metabolic diseases.

Altimmune

This biopharmaceutical company develops peptide-based therapeutics for patients with obesity and liver diseases, including metabolic dysfunction-associated steatohepatitis and alcohol-associated liver disease.

Metsera

The company develops injectable and oral medicines for patients with obesity and metabolic diseases.

Metabolys

This biopharmaceutical company develops oral small molecules to treat metabolic diseases, specifically non-alcoholic steatohepatitis and type 2 diabetes, for the global healthcare market.

Resalis Therapeutics

This company develops non-coding RNA therapies to treat metabolic disorders, including obesity and fatty liver disease, for patients with unmet medical needs.

Kailera

This biopharmaceutical company develops injectable and oral therapies for the treatment of obesity and related metabolic conditions.

89bio (NASDAQ: ETNB)

This biopharmaceutical company develops pegozafermin to treat patients with liver and cardio-metabolic diseases, including metabolic dysfunction-associated steatohepatitis and severe hypertriglyceridemia.